Clinical Trial

Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up

Study acronym: GlioConnect
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms. This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.
Trial Details
NCT Number NCT07628257
Lead Sponsor Centre Paul Strauss
Conditions Glioblastoma
Enrollment 80 participants
Start Date 2026-09-15
Primary Completion 2030-09-15 (estimated)
Study Completion 2030-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-04